News
Public · Published
Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer
Merck, known as MSD outside the US and Canada, reported that sacituzumab tirumotecan cut the risk of death by 32% and the risk of disease progression or death by 41% versus chemotherapy in certain patients with advanced or recurrent endometrial cancer in the Phase 3 TroFuse-005 trial.
Published:
Updated:
What happened
Merck, known as MSD outside the US and Canada, reported that sacituzumab tirumotecan cut the risk of death by 32% and the risk of disease progression or death by 41% versus chemotherapy in certain patients with advanced or recurrent endometrial cancer in the Phase 3 TroFuse-005 trial.
Confirmed
Global impact / market context
If approved, the drug could give Merck a new revenue stream in women's cancer care and strengthen its oncology lineup, which matters because new treatments can offset declining sales of older medicines and support long-term earnings growth.
Analyst inference
The readout puts an antibody-drug conjugate, which is a therapy that attaches a cell-killing drug to a targeted antibody, ahead in this cancer setting and could shape competition among drugmakers developing similar TROP2-targeted treatments for endometrial cancer.
Analyst inference
What to watch
- The TroFuse-005 data were presented at ESMO Congress 2026 and published in The Lancet, and regulators will likely review the full overall survival and progression-free survival results before any approval decision. Confirmed
- Merck and Kelun-Biotech may file for regulatory approval of sacituzumab tirumotecan in this endometrial cancer setting, so investors should watch for submission announcements and any priority review designations. Proposed
- Investors should track whether Merck expands the drug's testing to earlier stages of endometrial cancer and whether rival TROP2 antibody-drug conjugates report competing survival data that could pressure pricing and market share. Analyst inference
Evidence
- Original source link unavailable